Balaxi Pharmaceuticals Ltd (NSE: BALAXI) is a Hyderabad, Telangana-based company in the Health Care Distributors industry. With a market capitalisation of ₹115 Cr, it ranks #3,145 by market cap among the 6,189 Indian listed companies on FinBizNet, and #4 of 11 in Health Care Distributors. At ₹20.91 (as of 26 Oct 2026), the share price is 52.3% below its 52-week high of ₹43.85 and 37.6% above its 52-week low of ₹15.20. The share price is down 50.2% over one year and down 14.5% over three months.
| Current Price | ₹20.91 |
|---|---|
| Market Cap | ₹115 Cr |
| NSE Symbol | BALAXI |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors |
| P/E Ratio | 81.4 |
| Return on Equity | 0.59% |
| Return on Assets | 1.23% |
| 52-Week Range | ₹15.20 – ₹43.85 |
| 1-Year Price Change | -50.2% |
| 3-Month Price Change | -14.5% |
| Beta (1Y) | 0.81 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | balaxipharma.in |
| Revenue | ₹81 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 1.6% |
| EPS (Basic) | ₹0.24 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. The company was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
1. Specialized Wholesale-This segment engages in providing investment services.
1. Specialized Wholesale-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Trimurthi Ltd | ₹170 Cr | 49.1 | 7.99% | — | +48.6% |
| Achyut Healthcare Ltd | ₹168 Cr | 535.4 | 0.95% | — | +15.0% |
| Vaidya Sane Ayurved Laboratories | ₹154 Cr | — | 11.99% | — | -43.5% |
| Balaxi Pharmaceuticals Ltd | ₹115 Cr | 81.4 | 0.59% | ₹81 Cr | -50.2% |
| Chanfta Bhagat Pharma Ltd | ₹29 Cr | 9.7 | 2.91% | — | -5.1% |
| Medico Intercontinental Ltd | ₹23 Cr | -7.1 | -27.14% | ₹14 Cr | -34.9% |
| Rubra Medicaments Ltd. | ₹20 Cr | 13.4 | 12.67% | — | -37.7% |
| Zenlabs Ethica Ltd | ₹18 Cr | -9.1 | -20.44% | — | -12.8% |
| Nexus Surgical & Medicare Ltd | ₹14 Cr | 18.6 | 51.41% | — | +76.5% |
Listed by market capitalisation. Ratios are shown for context only.
Balaxi Pharmaceuticals Ltd is trading at ₹20.91, with a market capitalisation of ₹115 Cr.
Balaxi Pharmaceuticals Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors).
Balaxi Pharmaceuticals Ltd has a P/E of 81.4 and a return on equity of 0.59%.
Balaxi Pharmaceuticals Ltd is listed on the NSE under the symbol BALAXI.
Balaxi Pharmaceuticals Ltd's share price is down 50.2% over one year and down 14.5% over three months. Its 52-week range is ₹15.20 to ₹43.85.
In Q1 FY27, Balaxi Pharmaceuticals Ltd reported revenue of ₹81 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.24 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.